J

Active Director Director DIN 07569147
DIN 07569147 First appointment Aug 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2016
Shareholding value •••• Premium profile

About Jaseera

Data last updated:

Jaseera is a Director at Heilent Pharmaceuticals Private Limited (since 2016). The company operates in Pharma. Heilent Pharmaceuticals Private Limited reported revenue of ₹32.7 Lakh (FY 2025).

DIN 07569147
Primary Designation Director
Industry Pharma
First Appointment 17 Aug 2016
Oldest Company Age 10 yrs
Largest company Heilent Pharmaceuticals Private Limited · ₹32.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director17 Aug 20162016₹32.7 Lakh (FY 2025)Active

Board colleagues of Jaseera

NameDINCompanyDesignation
Sidheeque Ullattil07281121Heilent Pharmaceuticals Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Heilent Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Jaseera

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jaseera

Jaseera currently holds 1 directorship: Heilent Pharmaceuticals Private Limited (Director, since 17 Aug 2016, revenue ₹32.7 Lakh (FY 2025)).

Jaseera was first appointed on 17 Aug 2016 as Director at Heilent Pharmaceuticals Private Limited.

The current boards of Jaseera's companies include Sidheeque Ullattil (Heilent Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available